We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sign up to read this article for FREE!

After signing up, you'll start to receive regular news updates from us.

Microjet Reactor Creates Solutions for Safe Production of Nano- and Microparticles

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 2 minutes

A basic prerequisite for international competitiveness of the business location Germany is the research and development of innovative products and production processes in which nanotechnology makes a significant contribution as a key technology.

The symbiosis of microreaction technology and nanotechnology to produce the smallest particulate systems leads to novel perspectives for health, cosmetics and foods.

In the pharmaceutical industry, especially in the fields of drug delivery, in vivo diagnostics, medical implants and for application of innovative approaches for therapeutic concepts, it appears that novel solutions moves within reach.

The production of nanoparticles with conventional methods is usually expensive and only moderately controllable in a technical environment. The innovative, patented production technology of nano- and microparticles in a microjet reactor is in all technical aspects, physical and chemical parameters easily manageable, cost-effective and feasible in larger production scales leading to very high quality, homogeneous particles.

Efficient development of highly specialized, customized particles is made possible with combination of the novel technology with statistical methods, design of experiments.

The use of active pharmaceutical ingredients (APIs) with pharmaceutical excipients in a single nano- or microparticle expands the application potential far beyond only size miniaturization. The solubility improvement or the complete re-formulation of approved drugs with approved pharmaceutical excipients minimize substantially clinical development risk.

This allows a quick and inexpensive approval of new, patented formulations showing improved efficacy and lower side effects at the same time. All chemicals used in production are pharmaceutically harmless and a wide range of options for development of highly potent drug delivery systems is available. Furthermore there are no restrictions on application routes nor the use of sensitive biomolecules.

The technology is based on the use of a micro reactor in the middle of which, in simplified form, two fine impinging jets with the reactants as dissolved constituents meet. Thanks to the patented reactor design, there is a very fast and intensive mixing of these jets.

A mixing time of below 0.1 ms is achieved. In this way, ideal conditions for the formation of particles are created. Other advantages of the microjet reactor technology are controllable particle size, very narrow particle size distribution and the ability to scale up the process.

The production takes place in a completely closed system, there is almost no risk of microbiological contamination. The production facilities are designed under the highest quality standards in accordance with the GMP requirements.

The introduction of the microjet reactor into the life science field promises a significant and lasting contribution to the health of society and also to reinforce the competitiveness of pharmaceutical companies. Improving the efficacy of drugs, improving the formulation and the design and manufacture of innovative, superior drug delivery systems forms the main focus of development studies.

MJR PharmJet placed in Saarland, is capable of coming up with unique features superior to its competitors, such as the approach of the use of pharmaceutical ingredients with APIs in a single nano- or microparticle and the design of experiments for the efficient development of highly specialized, customized particles. The product portfolio of MJR PharmJet ranges from contract research services to marketing of its own formulation strategies and products.

The product offer is completed by the sale of microjet reactor production plants. Different formulation strategies and resulting concrete, final products using these formulation strategies are also included in the product portfolio of MJR PharmJet. In order to expand business activities MJR PharmJet offers cooperation alliances to strategic partners, these partnering activities can be adapted specifically to the ideas and needs of both sides.